GLP‑1s keep rising
Coverage this week flags the rapid rise—and growing scrutiny—of GLP‑1 receptor agonists: drugs developed for diabetes that are now widely used for weight management and being discussed for longevity and metabolic optimization Health Insight: Mar 14, 2026. The conversation centers on benefits, off‑label demand, and the need for evidence‑based deployment in wellness contexts.
Tirzepatide is projected to be the top-selling drug of 2026 with estimated global sales above $45 billion, while semaglutide variants are forecast at about $39.5 billion. emarketer.com The FDA completed a comprehensive safety review and asked makers to remove suicidal ideation and behavior warnings from Saxenda, Wegovy and Zepbound after reviewing 91 placebo‑controlled trials covering 107,910 patients. fda.gov CMS will run a short “Medicare GLP‑1 Bridge” from July 1 to December 31, 2026 and roll a longer BALANCE Model into Medicare Part D beginning January 1, 2027. cms.gov Under the Bridge, CMS set a $50 copayment for Wegovy and Zepbound and limited eligibility to beneficiaries with BMI ≥35 or BMI ≥27 plus clinical criteria. kff.org After shortages that stretched through early 2025, the FDA declared supplies stabilized and issued clarifications for compounders, while federal courts barred compounding of tirzepatide and manufacturers pursued litigation—Novo Nordisk reached a deal with Hims & Hers in March 2026 to sell branded product rather than compounded alternatives. pharmaceutical-technology.com Real‑world demand surged: prescriptions rose roughly 587% over five years per HealthVerity’s analysis, and Zocdoc reported appointment spikes with a 50% rise among women and a 71% rise among men seeking GLP‑1 consultations. blog.healthverity.com Clinical debates are sharpening: large trials like STEP showed about 15% average weight loss with semaglutide and analyses report roughly 39–40% of that loss can be lean mass, prompting geriatric and nutrition concerns. jamanetwork.com Meta‑analyses highlighted potential reductions in cardiovascular events and dementia risk but major reviews in journals such as JAMA and The Lancet call for longer‑term safety, comparative‑effectiveness and equity research before broad use for “metabolic optimization” or longevity. jamanetwork.com
